Bristol-Myers Squibb Company (BMY)

76.95
1.20 1.50
NYSE
Prev Close 75.80
Open 76.29
Day Low/High 76.08 / 77.25
52 Wk Low/High 53.22 / 78.17
Volume 13.36M
Exchange NYSE
Shares Outstanding 2129.06B
Market Cap 162.45B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Recession-Proof Dividend Stocks

3 Recession-Proof Dividend Stocks

The prospect of a potential recession this year means investors must be more vigilant than ever in selecting stocks for their portfolio.

7 Best Buys in Biotech and Drug Development

7 Best Buys in Biotech and Drug Development

Recently poor sector performance is creating opportunity for long-term investors.

Can Bristol-Myers Squibb Finally Make an Upside Breakout?

Can Bristol-Myers Squibb Finally Make an Upside Breakout?

Maybe third time's the charm.

Jobs Guess, Central Bankers Tighten Up, Thursday Smackdown, Correction's End?

Jobs Guess, Central Bankers Tighten Up, Thursday Smackdown, Correction's End?

Plus, while market breadth stunk yesterday, it was on lower trading volume, which is an encouraging sign.

Viagra to Vaccines: 8 Healthcare Favorites for 2022

Viagra to Vaccines: 8 Healthcare Favorites for 2022

Investment experts pick their favorites in the sector for 2022, ranging from diagnostics to medical devices and medical marijuana to drug development.

An Experienced Hand Launches 3 ETFs Under His Own Flag

An Experienced Hand Launches 3 ETFs Under His Own Flag

ETF veteran Kevin Kelly is the force behind Kelly ETFs, which this month introduced three funds with distinctly different focuses.

Options Play of the Week: A Biotech Back in a Buy Zone

Options Play of the Week: A Biotech Back in a Buy Zone

In this market environment, there is nothing wrong with a 'rinse, wash and repeat' trade.

Top Stock Picks for 2022 in Biotech and Genetics

Top Stock Picks for 2022 in Biotech and Genetics

Seven investment experts participating in Moneyshow's Top Picks 2022 report share their ideas for healthy portfolio gains in 2022.

Here's Our Best Dividend Stock for 2022

Here's Our Best Dividend Stock for 2022

Blue chip stock Bristol-Myers Squibb has a high dividend yield and an excellent pipeline.

Market Gets Down and Dreary

Market Gets Down and Dreary

As few seem interested in pre-holiday stock shopping, Monday shows extended indexes and names struggling to find support.

Let's Check Up on 2 Immunology-Focused Oncology ETFs

Let's Check Up on 2 Immunology-Focused Oncology ETFs

Here we'll look at the iShares Genomics Immunology and Healthcare ETF and the Cancer Immunotherapy ETF to see how they stack up.

2 'January Effect' Trading Candidates

2 'January Effect' Trading Candidates

I think these names will benefit from this theme, which I project will start to occur right after the Thanksgiving holiday this year.

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

Johnson & Johnson Joins the Breakup Club: Here's How to Play It

J&J will be separating into two distinct firms, but not right away.

I've Used a Strategy of Trade-Offs With 2 Biotech Stocks

I've Used a Strategy of Trade-Offs With 2 Biotech Stocks

I tend to only use this strategy to a great extent when I have a negative or neutral view on the overall market.

Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up

Glimmers of Hope in the Biotech Realm as M&A Activity Picks Up

A recent trio of acquisition deals indicates the doldrums in the sector may be over.

Don't Own Merck Stock Yet? Here's My Prescription

Don't Own Merck Stock Yet? Here's My Prescription

I am in this one for the medium to long term.

A Bristol-Myers Bounce? Here's How I'd Play It

A Bristol-Myers Bounce? Here's How I'd Play It

Keep in mind earnings are scheduled for Oct. 27 along with a $0.49 dividend on Sept. 30.

3 Big Pharma Buys for Dividend Investors

3 Big Pharma Buys for Dividend Investors

In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.

Would-Be Buyers Should Wait for a Dip in Bullish Prothena

Would-Be Buyers Should Wait for a Dip in Bullish Prothena

The shares of the under-the-radar biotech have had a strong run in recent months, so traders might want to watch for a pullback to buy.

Pfizer's Charts Suggest a Strong Rally Ahead

Pfizer's Charts Suggest a Strong Rally Ahead

Here are our latest price targets.

Jim Cramer: The Drug Cos. Are at Full Strength

Jim Cramer: The Drug Cos. Are at Full Strength

We're seeing a group move in pharma right now, so let's sort it out, pill by pill.

Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets

Resilience? Stagflation Signs, Nvidia Action, Fed Hawks on Deck, Booster Rockets

A wall of liquidity seems to absorb every dip. But there are also enough reasons to be ever vigilant.

Jim Cramer: To Every Market Sector, Turn, Turn, Turn

Jim Cramer: To Every Market Sector, Turn, Turn, Turn

To the melody of the Byrds' famed song, I want you to know: There's a time to buy the industrials, a time to sell the banks; a time to bid for health cares, a time to dump the techs. ...

China 'Rules', Defense Stocks, Infrastructure Package, FOMC, Earnings

China 'Rules', Defense Stocks, Infrastructure Package, FOMC, Earnings

What if Beijing plays the power game with foreign firms reliant upon Chinese revenue, Chinese labor, or simply Chinese economic growth?

Bristol-Myers Squibb Makes Its Upside Breakout

Bristol-Myers Squibb Makes Its Upside Breakout

Here's what traders and investors should do next.

Here Is Something Cathie Wood and I Agree On

* The attractiveness of Coinbase  Speaking of ARK Invest, the ETF complex has purchased Coinbase on nearly three-quarters of the days it has been public. All transactions below are dated May 20: FUND Direction Ticker CUSIP Name Shares % of ETF ARKF ...

2 Biotech Stocks That Appear Undervalued Based on Their Prospects

2 Biotech Stocks That Appear Undervalued Based on Their Prospects

Agenus Inc. and uniQure N.V. recently have announced positive news developments that should boost their long-term prospects.

Jim Cramer: Here's What Can Go Higher

Jim Cramer: Here's What Can Go Higher

Let's look at the companies that can go up, and the ones that can't.